Navigation Links
Europe is joining forces against neglected parasitic diseases
Date:3/4/2014

The project involves 10 European partners, 5 Brazilian partners (who operate in the region where the diseases are endemic) and 2 Australian partners. They will all be meeting on 17 and 18 March at the Institute of Genetics and Molecular and Cellular Biology (Inserm / CNRS / University of Strasbourg Joint Research Unit), to get the project started.

Schistosomiasis, leishmaniasis, Chagas disease and malaria are regarded as neglected diseases because the effort and funds put into developing new treatment and control methods have not been commensurate with their catastrophic human impact. They affect people in developing countries, essentially in Africa, the Middle East, South America and eastern Asia, in tropical and sub-tropical regions. Around one billion people are regularly exposed to these diseases, which cause almost one million deaths every year.

At present, there is no vaccine against these parasites. Furthermore, the efficacy of existing treatments is limited, either by the side effects or by the current or potential development of resistance. Consequently, the A-PARADDISE consortium, which is coordinated by Inserm and headed by Raymond Pierce - Director of Research at the Centre for Infection and Immunity in Lille - is focusing on developing new drugs against these parasitoses.

The A-PARADDISE project will use a methodology that has already been tried and tested during a previous project of a similar scale (SEtTReND), which aimed to develop drugs against schistosomiasis. The researchers investigated histone-modifying enzymes (HME), which determine the structure of the parasite's chromosomes. It was demonstrated that some HME inhibitors induce cell death, which makes them toxic to this parasite. This research provided the proof of concept that HMEs act on the schistosomiasis parasite, and has led to the development of a bank of candidate compounds which can rapidly be tested against other human parasites.

Thanks to the new project A-PARADDISE, researchers will be able to put the basic principle into practice and build on it by creating a unique platform for testing anti-parasitic drugs targeting HMEs, with a view to incorporating them into a clinical development programme. The experimental method consists in physically and virtually testing the efficacy and the toxicity of the compounds, in vitro and in vivo.

The ultimate objective of the A-PARADDISE project is to provide several candidate treatments against the four parasites and to pave the way for clinical trials in the near future.

To ensure the success of the project, the participants were all selected for their high level of expertise in their respective fields: high-throughput screening, computer-aided screening, the production of recombinant proteins, next generation sequencing, phenotypic tests, toxicology and pharmacology.


'/>"/>

Contact: Raymond Pierce
Raymond.Pierce@pasteur-lille.fr
33-320-877-783
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related biology news :

1. European flood risk could double by 2050
2. Researchers shed new light on the genetic history of the European beaver
3. European Union launches Nordic climate innovation center
4. Unique new dataset CLIMBER: Climatic niche characteristics of the butterflies in Europe
5. Are invasive plants a problem in Europe? Controversial views among invasion biologists
6. Scandinavia joins European Unions main climate innovation initiative
7. Blue eyes and dark skin, thats how the European hunter-gatherer looked
8. European epilepsy consortium identifies new gene for severe childhood epilepsy
9. Meloidogyne mali: A new invasive plant parasitic nematode in Europe
10. Aspartame passes stiff review by European Food Safety Authority
11. Europes rarest orchid rediscovered on lost world volcano in the Azores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced ... "Digital Life Alliance" established by iCarbonX, the ... to build a "Global Digital Health Ecosystem that ... a combination of individual,s biological, behavioral and psychological ... agreement between the companies, SomaLogic will provide proteomics ...
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... 18, 2017  Market Research Future published a half-cooked research report ... to grow at a CAGR of 12% during the period 2016 ... ... the abnormal cell division without any control. These abnormal cells have ... These cancer cells can spread to other parts of the body ...
(Date:1/17/2017)... , Jan. 17, 2017 The ... at a CAGR of around 7.5% over the ... 2025. Some of the prominent trends that the ... incidences of diseases & graft transplant surgeries and ... Material the market is categorized into immunomodulatory biomaterials, ...
(Date:1/17/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... and earnings conference call will be broadcast live over ... a.m. Eastern Time.  A news release detailing the quarterly ... a.m. Eastern Time the morning of the conference call. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:1/17/2017)... , Jan. 17, 2017 Research and ... "Molecular Diagnostics - Technologies, Markets and Companies" to ... ... has increased remarkably during the past few years. More than ... molecular diagnostics and 342 of these are profiled in the ...
Breaking Biology Technology: